CRAWLEY, United Kingdom
Regulatory News:
humediQ GmbH has initiated legal proceedings against two companies in the Elekta (STO:EKTAB) (EKTA-B.ST) group.
The dispute relates to an agreement from October 2011 for exclusive supply of Identify™ under the Elekta label. Identify is a patient identification and setup verification product.
Recently, a dispute arose between Elekta and humediQ relating to certain terms of the agreement. Now, humediQ is claiming damages from Elekta for an amount of approximately EUR 16 million.
Elekta believes that the claims have no merit and intends to defend them vigorously and assert counterclaims against humediQ.
# # #
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 20:00 CET on December 2, 2014.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.
This information was brought to you by Cision http://news.cision.com
CONTACT
For further information, please contact:
Elekta AB
Gert
van Santen, +31 653 561 242
Group Vice President Corporate
Communications
gert.vansanten@elekta.com
Time
zone: CET: Central European Time
